Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)
China
· Delayed Price · Currency is CNY 40.68
+0.96 (2.42%)
Mar 10, 2026, 9:55 AM CST
SHA:603590 Revenue
Beijing Konruns Pharmaceutical had revenue of 231.35M CNY in the quarter ending September 30, 2025, a decrease of -4.12%. This brings the company's revenue in the last twelve months to 871.31M, up 2.96% year-over-year. In the year 2024, Beijing Konruns Pharmaceutical had annual revenue of 825.40M, down -10.28%.
Revenue (ttm)
871.31M
Revenue Growth
+2.96%
P/S Ratio
7.25
Revenue / Employee
1.30M
Employees
668
Market Cap
6.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 825.40M | -94.61M | -10.28% |
| Dec 31, 2023 | 920.01M | 53.29M | 6.15% |
| Dec 31, 2022 | 866.73M | 56.94M | 7.03% |
| Dec 31, 2021 | 809.78M | 1.14M | 0.14% |
| Dec 31, 2020 | 808.64M | -257.28M | -24.14% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lifecome Biochemistry | 587.04M |
| Shanghai OPM Biosciences | 354.91M |
| Shenzhen Weiguang Biological Products | 1.14B |
| GemPharmatech | 793.25M |
| R&G PharmaStudies | 789.45M |
| Xiangxue Pharmaceutical | 1.47B |
| Kexing Biopharm | 1.54B |
| Jiangsu Aidea Pharmaceutical Group | 720.67M |